FAQ on Aditxt Inc.'s Livestream Event and Its Autoimmune Therapeutics Subsidiary Adimune

What is the purpose of the Aditxt Inc. livestream on July 22, 2025?

The livestream aims to highlight Adimune Inc.’s innovative approach to autoimmune therapeutics, discuss upcoming milestones, and explore opportunities in the autoimmune disease market.

Who will be hosting and featuring in the Aditxt Inc. livestream?

Jack Marks of Wall Street Reporter will host the event, featuring Aditxt Co-founder and CEO Amro Albanna.

Where can I view the full press release about the livestream?

The full press release can be viewed at https://ibn.fm/kCEAa.

What is Aditxt Inc.’s mission?

Aditxt Inc. is dedicated to accelerating promising health innovations through its ecosystem of research institutions, industry partners, and shareholders, aiming to tackle significant societal challenges.

What programs does Aditxt Inc. currently operate?

Aditxt currently operates programs focused on immune health and precision health, with plans to introduce additional programs dedicated to public health and women’s health.

What are the conditions for the transactions with Appili Therapeutics Inc. and Evofem?

The closing of these transactions is subject to several conditions, including approval by the respective target shareholders and Aditxt raising sufficient capital to fund its obligations at closing.

Where can I find the latest news and updates relating to Aditxt Inc.?

The latest news and updates are available in the company’s newsroom at https://ibn.fm/ADTX.

What is InvestorWire?

InvestorWire is a specialized communications platform focusing on advanced wire-grade press release syndication for private and public companies and the investment community, part of the Dynamic Brand Portfolio @ IBN.